NF-κB pathway and IL-8 synthesis in host cells

The phrase "NF-κB pathway and IL-8 synthesis in host cells" does not correspond to a single canonical molecule or therapeutic target. It refers to two interconnected but distinct biological processes: the NF-κB signaling pathway and the synthesis of interleukin-8 (IL-8), also known as CXCL8. The NF-κB pathway is a central signaling cascade critical for the regulation of immune and inflammatory responses, cell survival, and proliferation. Signals activate the IκB kinase (IKK) complex, leading to degradation of IκB, release of NF-κB, and its nuclear translocation to induce transcription of target genes, including IL-8. IL-8 (CXCL8) is a chemokine produced in response to NF-κB activation in many cell types, acting as a major recruiter and activator of neutrophils and other leukocytes, implicated in inflammatory diseases and cancer. These are not a single target; listing them together as a target is not scientifically correct, though both are legitimate therapeutic targets on their own.

Other names

Nuclear factor kappa B pathwayNuclear factor κB pathwayCXCL8Neutrophil chemotactic factorC-X-C motif chemokine ligand 8

Mechanism of action for drugs targeting the components encompassed by this phrase include: for the NF-κB pathway, blocking phosphorylation and degradation of IκB to prevent NF-κB nuclear translocation and inhibit transcription of NF-κB target genes; for IL-8, neutralizing its activity or blocking its receptors (CXCR1/CXCR2) to reduce neutrophil recruitment, inflammation, and tumor progression.